Michael J Waddell, MD | |
5230 E Stop 11 Rd Ste 150, Indianapolis, IN 46237-6399 | |
(317) 865-5904 | |
(317) 865-5321 |
Full Name | Michael J Waddell |
---|---|
Gender | Male |
Speciality | Endocrinology |
Experience | 20 Years |
Location | 5230 E Stop 11 Rd Ste 150, Indianapolis, Indiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962420141 | NPI | - | NPPES |
11723372 | Other | CAQH | |
000000973567 | Other | ANTHEM | |
200442410 | Medicaid | IN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 01061407A (Indiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Franciscan Health Indianapolis | Indianapolis, IN | Hospital |
Franciscan Health Mooresville | Mooresville, IN | Hospital |
Indiana University Health | Indianapolis, IN | Hospital |
Indiana University Health Bloomington Hospital | Bloomington, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Franciscan Physician Network | 3072790682 | 989 |
News Archive
Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.
Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients.
In a recent study, combat exposure among Army enlisted women was associated with an increased likelihood of developing behavioral health problems post-deployment, including post-traumatic stress disorder (PTSD), depression, and at-risk drinking.
A new study to be presented at the American Association for the Advancement of Science (AAAS) in February 2020 will report on the generation of the world's first artificially created bacterial genome using a digital design algorithm along with the synthesis of DNA building blocks on a large scale. This genome takes form by chemical rather than template-based synthesis. The research is published in the journal Proceedings of the National Academy of Sciences.
› Verified 3 days ago
Entity Name | Franciscan Physician Network |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1225327984 PECOS PAC ID: 3072790682 Enrollment ID: O20110608000486 |
News Archive
Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.
Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients.
In a recent study, combat exposure among Army enlisted women was associated with an increased likelihood of developing behavioral health problems post-deployment, including post-traumatic stress disorder (PTSD), depression, and at-risk drinking.
A new study to be presented at the American Association for the Advancement of Science (AAAS) in February 2020 will report on the generation of the world's first artificially created bacterial genome using a digital design algorithm along with the synthesis of DNA building blocks on a large scale. This genome takes form by chemical rather than template-based synthesis. The research is published in the journal Proceedings of the National Academy of Sciences.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Michael J Waddell, MD Po Box 781076, Detroit, MI 48278-1076 Ph: (317) 528-4800 | Michael J Waddell, MD 5230 E Stop 11 Rd Ste 150, Indianapolis, IN 46237-6399 Ph: (317) 865-5904 |
News Archive
Human Genome Sciences, Inc. today announced that Novartis has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C. In November 2009, HGS submitted a Biologics License Application (BLA) for ZALBIN to the FDA in the United States.
Joslin scientists, in collaboration with researchers from the Harvard School of Public Health and Italian research institutes, have identified a previously unknown genetic variant associated with an increased risk of coronary heart disease (CHD) in type 2 diabetic patients.
In a recent study, combat exposure among Army enlisted women was associated with an increased likelihood of developing behavioral health problems post-deployment, including post-traumatic stress disorder (PTSD), depression, and at-risk drinking.
A new study to be presented at the American Association for the Advancement of Science (AAAS) in February 2020 will report on the generation of the world's first artificially created bacterial genome using a digital design algorithm along with the synthesis of DNA building blocks on a large scale. This genome takes form by chemical rather than template-based synthesis. The research is published in the journal Proceedings of the National Academy of Sciences.
› Verified 3 days ago
Irene A Carrothers, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1701 Senate Blvd, Indianapolis, IN 46202 Phone: 317-963-8776 Fax: 317-963-5285 | |
Liam P Howley, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1001 West 10th St Opw-m200, Indiana University Department Of Medicine, Indianapolis, IN 46202 Phone: 317-630-6560 | |
Cristina Nancy Perez Chumbiauca, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-5000 | |
Dr. Andrew Jonathen Ortega, DO Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 702 Rotary Cir, Indianapolis, IN 46202 Phone: 317-278-4427 | |
Lawrence John Born, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 8424 Naab Rd, #3-j, Indianapolis, IN 46260 Phone: 317-872-7396 Fax: 317-879-8328 | |
Brian T Robinson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1001 W 10th St, Indianapolis, IN 46202 Phone: 317-630-7979 Fax: 317-630-2668 | |
Steven T Hugenberg, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 550 University Blvd, Indianapolis, IN 46202 Phone: 317-944-8660 |